About us

Energenesis Biomedical has received CRO notification that its Phase I IND application for "ENERGI-F705PD," an oral Parkinson's treatment, has been conditionally approved by the Ministry of Health and Welfare to begin clinical trials.

Energenesis Biomedical Signs MOU with Taiwan Tanabe Seiyaku Co., Ltd., a subsidiary of Mitsubishi Tanabe Pharma Corporation, Japan, for the Commercialization Rights of F703DFU in Taiwan and Southeast Asia (ASEAN)

EB Announces Exclusive Licensing Agreement with PBI Portugal Unipessoal Lda., a wholly owned subsidiary of the German group Pharma Bavaria International

EB Receives Notification from CRO Regarding IND Submission to TFDA for Phase I Clinical Trial of ENERGI-F705PD, an Oral Treatment for Parkinson's Disease.

EB's proprietary 'METHOD FOR TREATING EPIDERMO-LYSIS BULLOSA' has been granted patent approval by the Intellectual Property Office

Energenesis's Novel Diabetic Foot Ulcer Gel Wins Excellence Award in Innovation Technology at 2024 Taipei Biotech Awards

Australian Patent Granted for "METHODS FORTREATING DIABETIC ULCER" Following PCT National Phase Entry

Thank you for meeting us at 2024 BIO Europe Spring

We welcome you to visit us at 2024 EWMA Conference

Meet us at 2024 BIO International Convention